General

Single-Dose CRISPR Therapy Achieves Durable Lipid Lowering via In Vivo Base Editing

A new single-dose CRISPR therapy achieves durable lipid lowering by inactivating ANGPTL3, paving the way for first-in-human trials.

S
SciTech Editorial Team
Newsroom
··2 min read
Single-Dose CRISPR Therapy Achieves Durable Lipid Lowering via In Vivo Base Editing
Researchers have unveiled a groundbreaking single-course treatment for atherosclerotic cardiovascular disease, a leading global health concern driven by high levels of low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins. Despite the availability of multiple approved lipid-lowering medications, the majority of patients continue to fail to reach target lipid levels under standard chronic care models. This new approach utilizes an infusion of guide RNA and mRNA encoding a CRISPR adenine base editor, encapsulated within a GalNAc–lipid nanoparticle, to achieve durable, liver-selective inactivation of angiopoietin-like 3 (ANGPTL3), a known driver of elevated lipid concentrations. The methodology relies on precision gene editing to introduce a specific DNA base-pair change at the target ANGPTL3 locus. In vitro analyses using human liver cells confirmed that the base editor operates with high specificity, showing no detectable off-target editing at any of approximately 3,000 candidate sites or treatment-related structural variants. This level of precision is critical for ensuring the safety of in vivo gene therapies, as it minimizes the risk of unintended genetic modifications that could have long-term health consequences. In nonhuman primate models, the targeted inactivation of ANGPTL3 was well-tolerated and resulted in a mean reduction of over 90% in circulating ANGPTL3 protein. Crucially, the durability of this effect was confirmed for up to three years following a single dose, suggesting a potential shift from chronic daily medication to a one-time therapeutic intervention. These findings represent a significant milestone in the field of gene therapy for metabolic disorders. Furthermore, in mouse and nonhuman primate models of hyperlipidemia, the gene inactivation was associated with substantial reductions in lipid markers. Specifically, LDL-C levels decreased by approximately 40 to 50%, while triglycerides dropped by 50 to 70%. These robust results provide the scientific foundation for the initiation of an ongoing first-in-human clinical trial, targeting patients with refractory hyperlipidemia syndromes who have not responded to conventional treatments. The broader implications of this research are profound for the cardiovascular industry. If successful in human trials, this technology could redefine the management of lipid disorders, offering a permanent solution for patients at high risk of heart disease and stroke. However, challenges remain in scaling up the production of lipid nanoparticles and ensuring long-term safety in diverse human populations. As the clinical trial progresses, the scientific community will closely monitor the data to determine if this single-dose approach can become a standard of care for refractory hyperlipidemia.

Share

More from this section: General